anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In the study, it was emphasized that the messages to be played to the patient should be 3-5 minutes and simple terms should be used in a way that can be understood by individuals with low education level. Written informed consent was obtained from the patient and the patient's relatives before the application. In the message recorded by a patient's relative decided by the patient's family members, the patient's relative said what he/she wanted to say to the patient and recorded it using a voice recorder. The researcher had a preliminary interview with the patient's relative before the voice recording was taken about the use of the voice recorder and the content of the message in order to prevent the messages from negatively affecting the patient. The voice recording created by the patient's relative was played to the patient by the researcher using a music pillow. After the patient listened to the audio recording, it was erased under the witness of the patient's relative.In this randomised, controlled, experimental study, patients were randomised into intervention and control groups according to gender and age groups. In the preliminary interviews with the family members of the patients in the intervention group, the message content was discussed with the relatives of the patients before the voice recording was taken and carefully prepared to prevent negative effects. After the patient's condition was stable, the pretest was administered 15 minutes before (T1) the voice recording of the patient's relative was played through the music pillow.After the application, two more tests were applied at 15 (T2) and 30 (T3) minutes. After the condition of the patients in the control group was stable, the pre-test was administered, then the patient was given routine information (Your mother/father/daughter/son/... is at the door, is there anything you want to tell them? I can convey and give feedback.). After the information, two more tests were administered at 15 and 30 minutes.
Oral Tacrolimus (Tablet form) 0.2mg/kg/day starting dose. Targeting trough level of Tacrolimus (T0) 5-7 ng/ml.
OBJECTIVES: This study aimed to perform a meta-analysis of the short-term impact of ischaemic postconditioning (IPoC) on myocardial injury in ST elevation myocardial infarction (STEMI) using surrogate cardiac biomarkers.
METHODS: Eligible studies were identified using several article databases. Randomised controlled trials published between 1 January 2000 and 1 December 2021 comparing IPoC to standard of therapy in STEMI patients were included in the search. Outcomes included surrogates of myocardial injury, specifically peak troponin, creatine-kinase (CK) and CK myoglobin binding (CK-MB) enzyme levels.
RESULTS: 11 articles involving 1273 patients reported on CK-MB and 8 studies involving 505 patients reported on CK. Few studies used troponin as an outcome, thus, a subanalysis of troponin dynamics was not performed. Meta-regression analysis demonstrated no significant effect of IPoC on peak CK-MB (effect size -0.41, 95% CI -1.15 to 0.34) or peak CK (effect size -0.42, 95% CI -1.20 to 0.36). Linear regression analysis demonstrated a significant correlation between a history of smoking and CK-MB in the IPoC group (p=0.038).
CONCLUSIONS: IPoC does not seem to protect against myocardial injury in STEMI, except possibly in smokers. These results resonate with some studies using imaging techniques to ascertain myocardial damage. More research using troponin and cardiac imaging should be pursued to better assess the effects of IPoC on cardiovascular outcomes in STEMI.
BACKGROUND: Many studies reported the presence of adenomas with high-grade dysplasia (HGD) at index colonoscopy increased the incidence of advanced neoplasia (AN) and colorectal cancer (CRC) following. However, the conclusion remains obscure due to lack of studies on the specific population of adenomas with HGD. This study aimed to assess the long-term risk of AN and CRC after removal of adenomas with HGD.
METHODS: A total of 814 patients who underwent adenomas with HGD removal between 2010 and 2019 were retrospectively analyzed. The outcomes were the incidences of AN and CRC during surveillance colonoscopy. Cox proportional hazards models were utilized to identify risk factors associated with AN and CRC.
RESULTS: During more than 2000 person-years of follow-up, we found that AN and CRC incidence densities were 44.3 and 4.4 per 1000 person-years, respectively. The 10-year cumulative incidence of AN and CRC were 39.1% and 5.5%, respectively. In the multivariate model, synchronous low-risk polyps (HR 1.80, 95% CI 1.10-2.93) and synchronous high-risk polyps (HR 3.99, 95% CI 2.37-6.72) were risk factors for AN, whereas participation in surveillance colonoscopy visits (HR 0.56, 95% CI 0.36-0.88 for 1 visit; HR 0.10, 95% CI 0.06-0.19 for ≥ 2 visits) were associated with decreased AN incidence. Additionally, elevated baseline carcinoembryonic antigen (CEA) level (HR 10.19, 95% CI 1.77-58.59) was a risk factor for CRC, while participation in ≥ 2 surveillance colonoscopy visits (HR 0.11, 95% CI 0.02-0.56) were associated with decreased CRC incidence. Interestingly, for 11 patients who developed CRC after removal of adenomas with HGD, immunohistochemistry revealed that 8 cases (73%) were deficient mismatch repair CRCs.
CONCLUSIONS: Patients who have undergone adenoma with HGD removal are at higher risk of developing AN and CRC, while surveillance colonoscopy can reduce the risk. Patients with synchronous polyps, or with elevated baseline CEA level are considered high-risk populations and require more frequent surveillance.
INTRODUCTION: Growing evidence suggests a causal role for atherosclerotic vascular disease in cognitive impairment and dementia. Atherosclerosis may present as monovascular disease (monoVD) or as widespread polyvascular atherosclerotic disease (polyVD). Evidence on the relationship between monoVD or polyVD and cognitive impairment is limited.
METHODS: We conducted a cross-sectional analysis of baseline data from the LipidCardio Study. The main outcome measure was the presence of cognitive impairment, defined as a Mini-Mental State Examination (MMSE) score < 26.
RESULTS: The mean age was 71.5 years, 30.3% were female, 17.3% had no evidence of large-vessel atherosclerosis, 71.1% had monoVD, and 11.7% had polyVD, defined as the presence of atherosclerosis in ≥ 2 vascular territories (coronary, cerebral, aortic, or lower extremity). A total of 21.6% had cognitive impairment according to the prespecified cutoff (MMSE < 26). Overall, the odds of cognitive impairment increased for each additional vascular territory affected by atherosclerosis [adjusted odds ratio 1.76, 95% confidence interval (CI) 1.21-2.57, p = 0.003]. Furthermore, there was evidence for an interaction between vascular disease and chronic kidney disease (CKD). The odds of cognitive impairment were not greater in the monoVD subgroup compared to those without any atherosclerosis, if CKD was absent (OR 0.98, 95% CI 0.48-2.10; p = 0.095), while the odds ratio (OR) of cognitive impairment with polyVD compared to no atherosclerosis was 2.71 (95% CI 1.10-6.92; p = 0.031). In contrast, in patients with CKD, both monoVD and polyVD were associated with significantly higher odds of cognitive impairment than no atherosclerosis.
CONCLUSIONS: PolyVD is associated with increased odds of cognitive impairment. MonoVD is associated with cognitive impairment only in the presence of CKD.
Part 1 (Cycle 1; 28 days): The first cohort of 3 participants will receive 25 micrograms per meters squared (μg/m\^2) of E7130, on Day 1 and Day 15 as an intravenous infusion. If a drug-related Grade 2 or higher toxicity excluding clinically insignificant events is not observed in the initial cohort, dose-limiting toxicities (DLTs) will be evaluated in successive dose levels with single participants until such a toxicity is observed. Once the maximum tolerated dose (MTD) will be determined. Part 2: Participants with squamous cell carcinoma of the head and neck and urothelial carcinoma will be evaluated at the dose level determined in Part 1 in a 2-week or in a 3-week regimen based on the evaluations in Part 1.
This leg will then perform low-load resistance training (30% of 1-RM) including 3 sets of 15 knee extensions performed as fast as possible while seated upright in a knee extension weight machine. Sets will be interspersed with 30 seconds rest. This leg will always perform the training with blood flow restriction.
The present invention relates to the composition of a bioadhesive endoparasiticidal gel based on doramectin, having a high degree of adhesion to equine oral mucosa and having a sweet flavor greatly facilitating the dosing thereof, methods for the preparation thereof and the use thereof. Gastrointestinal helminthosis is a parasitic condition caused by nematodes of diverse families causing serious gastrointestinal disorders in equine livestock. Control of this illness is of great importance and advantageously achievable through the use of suitable antihelmintic agents such as doramectin, which is a chemical compound widely administered by parenteral route and infrequently by oral route in liquid form due to the organoleptic and physicochemical characteristics of the compositions known up to the present. The present invention demonstrates that it is possible to administer doramectin in the dosage form of an oral gel at concentrations of up to 5.0% weight/volume, overcoming the organoleptic and physicochemical restrictions of the compositions known up to the present. Factors never heretofore included in oral endoparasiticidal compositions based on doramectin, presenting a wide differential advantage compared with the compositions known up to the present. These and other features, objectives and advantages of the present invention will be appreciated by the person skilled in the art from the detailed description provided below in the present document, as well as in the attached claims.
BACKGROUND: The impact of cigarette smoke (CS) on lung diseases and the role of microbiome dysbiosis in chronic obstructive pulmonary disease (COPD) have been previously reported; however, the relationships remain unclear.
METHODS: Our research examined the effects of 20-week cigarette smoke (CS) exposure on the lung and intestinal microbiomes in C57BL/6JNarl mice, alongside a comparison with COPD patients' intestinal microbiome data from a public dataset.
RESULTS: The study found that CS exposure significantly decreased forced vital capacity (FVC), thickened airway walls, and induced emphysema. Increased lung damage was observed along with higher lung keratinocyte chemoattractant (KC) levels by CS exposure. Lung microbiome analysis revealed a rise in Actinobacteriota, while intestinal microbiome showed significant diversity changes, indicating dysbiosis. Principal coordinate analysis highlighted distinct intestinal microbiome compositions between control and CS-exposed groups. In the intestinal microbiome, notable decreases in Patescibacteria, Campilobacterota, Defferibacterota, Actinobacteriota, and Desulfobacterota were observed. We also identified correlations between lung function and dysbiosis in both lung and intestinal microbiomes. Lung interleukins, interferon-ɣ, KC, and 8-isoprostane levels were linked to lung microbiome dysbiosis. Notably, dysbiosis patterns in CS-exposed mice were similar to those in COPD patients, particularly of Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 4 patients. This suggests a systemic impact of CS exposure.
CONCLUSION: In summary, CS exposure induces significant dysbiosis in lung and intestinal microbiomes, correlating with lung function decline and injury. These results align with changes in COPD patients, underscoring the important role of microbiome in smoke-related lung diseases.
FIELD: organofluoric compounds, medicine. SUBSTANCE: emulsion of perorganofluoric compounds (PFOS) for intravascular administration consists of rapidly eliminating perfluorocarbon and slowly eliminating perfluorinated tertiary amine and involves additionally at least three species of PFOS admixtures taken in small amounts. PFOS admixtures are similar by structure and physical- -chemical properties to basic PFOS. Emulsion comprises also minor admixtures of H-perfluoroalkanes. PFOS emulsion is stabilized with copolymer polyoxyethylene-polyoxypropylene. In preparing emulsion a stabilizing agent is heated at temperature below 75 C, all components are saturated with carbon dioxide and homogenization is carried out with carbon dioxide blowing. Proposed method ensures to minimize peroxides formation and therefore to reduce reactivity of emulsions. Components of composition causes stability of emulsion in storage and in blood circulation and low viscosity of PFOS emulsion that provides high dynamic oxygen capacity of the preparation and improves delivery of oxygen to tissues. Invention proposes to use PFOS emulsions as agent for treatment air-fat embolism, obliterating damages of limb vessels and also for prophylaxis of toxic damages caused by different xenobiotics. EFFECT: improved preparing method of emulsion, treatment and prophylaxis, valuable medicinal properties. 19 cl, 6 tbl, 8 ex
Loss of heterozygosity (LOH) has been reported to occur in HLA regions in cervical intraepithelial neoplasia (CIN) and cervical cancer. However, the details of how this is related to the progression of CIN have been unclear. In this study, we examined the human papillomavirus (HPV) antigen-presenting capacity of people with CIN and the significance of LOH of HLA class I in the progression of CIN. It was shown that differences in antigen-presenting capacity among each case depended on HLA types, not HPV genotypes. Focusing on the HLA type, there was a positive correlation between antigen-presenting capacity against HPV and the frequency of allelic loss. Furthermore, the lost HLA-B alleles had a higher HPV antigen-presenting capacity than intact alleles. In addition, frequency of LOH of HLA class I was significantly higher in advanced CIN (CIN2-3) than in cervicitis or early-stage CIN (CIN1): around half of CIN2-3 had LOH of any HLA class I. Moreover, the antigen-presenting capacity against E5, which is the HPV proteins that facilitate viral escape from this immune surveillance by suppressing HLA class I expression, had the most significant impact on the LOH in HLA-B. This study suggests that HPV evades immune surveillance mechanisms when host cells lose the capacity for antigen presentation by HLA class I molecules, resulting in long-term infection and progression to advanced lesions.
BACKGROUND AND OBJECTIVES: Deficiencies of protein C (PC) or protein S (PS) are rare diseases, characterized by mutations in the PC or PS genes, which encode plasma serine proteases with anti-coagulant activity. Severe PC or PS deficiencies manifest in early life as neonatal purpura fulminans, a life-threatening heamorrhagic condition requiring immediate treatment. First-line treatment involves replacement therapy, followed by maintenance with anti-coagulants. Replacement therapy with specific protein concentrates is currently only limited to PC, and therefore, a PC + PS concentrate represents a useful addition to therapeutic options, particularly for severe PS deficiency. Further, the production of a PC + PS concentrate from unused plasma fractionation intermediates would impact favourably on manufacturing costs, and consequently therapy prices for patients and health systems.
MATERIALS AND METHODS: Several chromatographic runs were performed on the same unused plasma fractionation intermediates using different supports to obtain a PC/PS concentrate. The best chromatographic mediums were chosen, in terms of specific activity and recovery. A full process of purification including virus inactivation/removal and lyophilization steps was set up.
RESULTS: The final freeze-dried product had a mean PC concentration of 47.75 IU/mL with 11% of PS, and a mean specific activity of 202.5 IU/mg protein, corresponding to over 12,000-fold purification from plasma.
CONCLUSION: The development of a novel concentrated PC/PS mixture obtained from a waste fraction of other commercial products could be used for its potential therapeutic role in the management of neonatal purpura fulminans pathology.
This study will be a double-blind randomized controlled trial to investigate the utility of prochlorperazine maleate versus placebo for the chemoprophylaxis of acute mountain sickness on rapid ascent to 4,348 meters, specifically the summit of Mount Blue Sky in the Mount Blue Sky Wilderness. Participants will be evaluated for AMS utilizing the 2018 LLQ both the evening of and morning after ascent. The primary outcome will be the presence of AMS, defined by a 2018 LLQ score equal to or greater than 3, including the presence of a headache at any measured point during the study. Individuals will convene the morning of the study in Golden, Colorado where they will receive breakfast and either placebo or prochlorperazine. They will then be driven to Summit Lake where they will break for lunch and receive the second dose of placebo or prochlorperazine. They will then hike to the Mount Blue Sky summit where they will receive their third and final dose of either placebo or intervention, spend the night in the structures at the summit, and be assessed for AMS via LLQ. In the morning, they will be assessed for AMS again, receive breakfast, and then be driven back to the original meeting point. They will be monitored by Emergency Physicians at all points during the study.
Randomized Control Trail (RCT) will be used in the study. Participants will be dived into experimental group and control group. Each group will includes 30 participants.The physiotherapy program intervention will includes cervical traction, cervical mobilization, Sub occipital release, Muscle energy technique. and ultra sound with parameters 5 min × 3 times × 4 weeks, 1 MHz, continuous: 1.5 W/cm2; pulsed: 2.5 W/cm2, for study group.
A retrospective analysis for control group was conducted on patients with PSVT reciecing RFA who met the inclusion and exclusion criteria and visited at the First Affiliated Hospital of Ningbo University the Third People's Hospital of Chengdu, the Xiamen Cardiovascular Hospital of Xiamen University, the First Hospital of Jilin University, the Seventh People's Hospital of Zhengzhou, Shanghai General Hospital, and Jiangxi Provincial People's Hospital from October 2022 to June 2024. 214 patients approached by RFA were matched 1:1 by propensity score to a similar population treated by PFA. Basic clinical information, procedural data, as well as the efficiency and safety of 1-year follow-up were collected and analyzed.
1. A compound of the formula:   or a pharmaceutically acceptable salt or solvate thereof. 2. A compound according to Claim 1, which has a purity of more than 90%. 3. A compound according to Claim 1, which has a purity of at least 95%. 4. A compound according to Claim 1, which has a purity of at least 97%. 5. A compound according to Claim 1, which has a purity of at least 99%. 6. A pharmaceutical composition for treating HIV infection, comprising effective amount of the compound or salt or solvate thereof according to Claim 1 and a pharmaceutically acceptable carrier. 7. A pharmaceutical composition according to Claim 6 wherein the compound or salt or solvate thereof has a purity of more than 90%. 8. A pharmaceutical composition according to Claim 6 wherein the compound or salt or solvate thereof has a purity of at least 95%. 9. A pharmaceutical composition according to Claim 6 wherein the compound or salt or solvate thereof has a purity of at least 97%. 10. A pharmaceutical composition according to Claim 6 wherein the compound or salt or solvate thereof has a purity of at least 99%.
Systems and methods for generating synthesized medical images of a tumor are provided. A 3D mask of an anatomical structure generated from a 3D medical image and a 3D image of a plurality of concentric spheres are received. A 3D mask of a tumor is generated based on the 3D mask of the anatomical structure and the 3D image of the plurality of concentric spheres using a first 3D generator network. A 3D intensity map of the tumor is generated based on the 3D mask of the tumor and the 3D image of the plurality of concentric spheres using a second 3D generator network. A 3D synthesized medical image of the tumor is generated based on one or more 2D slices of the 3D intensity map of the tumor and one or more 2D slices of the 3D medical image using a 2D generator network. The 3D synthesized medical image of the tumor is output.
It is proposed to obtain a self-setting injectable calcium phosphate foam to use as biomaterial for bone regeneration and/or as substrate for tissue engineering. The suggested way is to foam a calcium phosphate cement by addition of surfactants, agitation and mechanical whipping of the same. The addition of the surfactants allows stabilizing air bubbles in the cement matrix, leading to a high macroporosity with interconnection between the pores. Obtaining a high macroporosity is very important for bone regeneration, because it facilitates the angiogenesis, the colonisation of the material by the bone tissue and the resorption of the same. Given the applications of the material, the selection of biocompatible surfactants is especially relevant. For this reason, it is suggested to use surfactants which are already approved for drugs used in parenteral applications.
Thiamine disulphide O, O1-succinate - and its alkali(ne earth) salts, is pref. used in human and veterinary medicine for treating vitamin B1 deficiency; as Mg salt for Mg therapy; pref. as vitaminising additive to food or cattle feedstuffs; and pref. as cosmetic agent in care of skin and hair. It is prepd. by esterifying thiamine disulphide with succinic acid, advantageously by reacting thiamine disulphide with succinic anhydride if necessary in presence of an acid acceptor, such as a tertiary base, e.g. pyridine, advantageously by heating in a solvent, such as CHCl3, which is evaporated, and (I) recrystallised and converted to its salts.
A solid thermoplastic synthetic resin and a plasticiser therefor are dissolved in a molten, normally solid, fatty acid or wax, the amount of acid or wax exceeding the amount of resin and the cooled composition aerated by kneading or agitation.  Resins specified are polyvinyl formal, acetal and butyral, polyacrylates, polystyrene, polymethyl methacrylate, vinyl acetate/chloride copolymer, polyisobutylene and polyvinyl ethyl ether.  As plasticisers, mineral oil, dibutyl, dimethyl and diamyl phthalates, triacetin, tripropionin and benzyl benzoate are specified.  Fatty acids and waxes specified are stearic, acid, carnauba, bees, montan, japan and paraffin waxes. Anodynes and fillers such as eugenol, guaicol, calcium and barium sulphates and diatomaceous earth may be added.  The kneading may be done under water.  Such aerated compositions are used for dental impressions.
Patients receive placebo PO BID for 8 weeks. Patients complete resistance exercises 3 days per week and undergo walking program at least 5 days per week for 8 weeks. After 8 weeks, patients may optionally receive ethyl icosapentate, complete resistance exercises, and undergo walking program for 4 weeks as in Group I.
The present disclosure relates to a sensor for the detection of analytes, in particular for the detection of biomolecules. The sensor includes a (bio)compatible sensing layer including a polymer matrix or gel matrix, particularly a polymer gel matrix, organic nanoparticles and, optionally, one or several cell adhesion layer(s). The cell adhesion layer(s) can be varied depending on the type of cells. In the presence of the analytes, the organic nanoparticles are capable of photon up-conversion emission. The sensor further optionally includes plasmonic metal nanoparticles. The present disclosure further relates to methods of producing such a sensor and to uses of such a sensor.